1. Home
  2. FPAY vs SCYX Comparison

FPAY vs SCYX Comparison

Compare FPAY & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FPAY
  • SCYX
  • Stock Information
  • Founded
  • FPAY 2003
  • SCYX 1999
  • Country
  • FPAY United States
  • SCYX United States
  • Employees
  • FPAY N/A
  • SCYX N/A
  • Industry
  • FPAY Diversified Commercial Services
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FPAY Consumer Discretionary
  • SCYX Health Care
  • Exchange
  • FPAY Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • FPAY 27.2M
  • SCYX 28.5M
  • IPO Year
  • FPAY N/A
  • SCYX 2014
  • Fundamental
  • Price
  • FPAY $1.08
  • SCYX $0.71
  • Analyst Decision
  • FPAY Strong Buy
  • SCYX
  • Analyst Count
  • FPAY 2
  • SCYX 0
  • Target Price
  • FPAY $3.25
  • SCYX N/A
  • AVG Volume (30 Days)
  • FPAY 86.5K
  • SCYX 145.5K
  • Earning Date
  • FPAY 08-05-2025
  • SCYX 08-07-2025
  • Dividend Yield
  • FPAY N/A
  • SCYX N/A
  • EPS Growth
  • FPAY N/A
  • SCYX N/A
  • EPS
  • FPAY N/A
  • SCYX N/A
  • Revenue
  • FPAY $139,800,732.00
  • SCYX $2,630,000.00
  • Revenue This Year
  • FPAY $16.58
  • SCYX $463.61
  • Revenue Next Year
  • FPAY N/A
  • SCYX $310.80
  • P/E Ratio
  • FPAY N/A
  • SCYX N/A
  • Revenue Growth
  • FPAY 19.51
  • SCYX N/A
  • 52 Week Low
  • FPAY $0.84
  • SCYX $0.66
  • 52 Week High
  • FPAY $2.37
  • SCYX $2.29
  • Technical
  • Relative Strength Index (RSI)
  • FPAY 43.10
  • SCYX 38.69
  • Support Level
  • FPAY $0.84
  • SCYX $0.67
  • Resistance Level
  • FPAY $1.17
  • SCYX $0.75
  • Average True Range (ATR)
  • FPAY 0.09
  • SCYX 0.04
  • MACD
  • FPAY -0.01
  • SCYX 0.00
  • Stochastic Oscillator
  • FPAY 58.70
  • SCYX 33.06

About FPAY FlexShopper Inc.

FlexShopper Inc is a financial technology company engaged in providing certain types of durable goods to consumers on a lease-to-own basis and providing lease-to-own (LTO) terms to consumers of third-party retailers and e-tailers. Its products include electronics, computers, furniture, mattresses, cameras and camcorders, audio, musical instruments, health, fitness and sports, video games, homes, gardens and tools, appliances, and vacuums on a payment, lease basis. The firm generates a majority of its revenue by leasing its products. The company enables consumers utilizing its e-commerce marketplace to shop for brand-name electronics, home furnishings, and other durable goods on a lease-to-own (LTO) basis.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: